Antimicrobial effect of a chlorhexidine-thymol varnish (Cervitec) in orthodontic patients. A prospective, randomized clinical trial.
The aim of the present investigation was to study the effect of combined application of a fluoride varnish (Fluor Protector) and an antimicrobial varnish (Cervitec) on the oral microflora, caries and gingival condition in patients receiving treatment with fixed orthodontic appliances. A total of 198 individuals (12 to 15 years old), scheduled for fixed orthodontic treatment, were randomized into 2 groups. Prior to bonding, the Cervitec and the control group received one application with Cervitec or a placebo every week for 3 weeks, respectively. In the Cervitec group. Fluor Protector was applied at bonding and Cervitec at the next visit, 6 weeks later. Each varnish was then applied every 12 weeks for 24 weeks. In the control group, the fluoride varnish was applied only at bonding and every 12 weeks. The Visible Plaque Index (VPI), the Gingival Bleeding Index (GBI), the White Spot Lesion Index (WSL) and the level of mutans streptococci in plaque and saliva were recorded 3 weeks prior to bonding and after 24 weeks. At bonding and after 12 weeks, only VPI, GPI, plaque and salivary mutans streptococcus counts were recorded. During the 3-week prebonding period, the mean VPI, GBI and mutans streptococci in plaque decreased in both groups. At bonding, the mean level of mutans streptococci in plaque was significantly lower in the Cervitec group than in the control group. The mean level of mutans streptococci was significantly lower after 12 weeks' bonding in the Cervitec group than in the control group. No effects on the other parameters were found during the 24 weeks.
Ogaard
B
B
Department of Orthodontics, Faculty of Dentistry, University of Oslo, Norway.
Larsson
E
E
Glans
R
R
Henriksson
T
T
Birkhed
D
D
D000293:Adolescent; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D002648:Child; D002710:Chlorhexidine / Q000627:therapeutic use*; D001840:Dental Bonding; D003736:Dental Cavity Lining; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005460:Fluorides, Topical / Q000627:therapeutic use; D006801:Humans; D016910:Orthodontic Brackets; D009971:Orthodontics, Corrective; D010512:Periodontal Index; D011140:Polyurethanes / Q000627:therapeutic use; D011446:Prospective Studies; D012821:Silanes / Q000627:therapeutic use; D013295:Streptococcus mutans / Q000187:drug effects; D013943:Thymol / Q000627:therapeutic use*; D013997:Time Factors
D000891:Anti-Infective Agents, Local; D004338:Drug Combinations; D005460:Fluorides, Topical; D011140:Polyurethanes; D012821:Silanes; C079161:chlorhexidine, thymol drug combination; D013943:Thymol; C022599:Fluor Protector; D002710:Chlorhexidine